Skip to main content

Table 2 Laboratory capacity questions

From: Feasibility of a randomized controlled trial to assess treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Saudi Arabia: a survey of physicians

Questions

Responders to the Question

Answer options

Responders

The source of blood products?

250

Blood bank in your facility

235 (94.0)

  

Blood bank from another facility

15 (6.0)

Feasibility of obtaining blood donation from specific groups (e.g., survivors of MERS-CoV)

237

Yes

130 (54.9)

The capability to screen for blood-borne viruses in donated blood (e.g., HIV, hepatitis, etc.)?

248

Yes

240 (96.8)

Ability to send suspected MERS-CoV samples to a reference laboratory for diagnosis?

226

Yes

173 (76.5)

 Turn-around time

164

1 day

15

2 days

24

3 days

44

4 days

15

5 days

24

6 days

3

7 days

22

9 days

1

10 days

7

14 days

6

15 days

1

21 days

2

 Methodologies for MERS-CoV testinga

205

Real-time PCR

Yes

135

No

10

Do not know

57

Sequencing

Yes

22

No

21

Do not know

110

Serology

Yes

51

No

21

Do not know

88

Other (please specify)

 

8

Available diagnostic work-up for severe acute respiratory infectiona

218

Blood cultures

Yes

205

No

4

Do not know

6

Urine bacterial antigen testing

Yes

153

No

28

Do not know

30

Viral antigen testing

Yes

146

No

36

Do not know

28

PCR for bacterial and viral testing

Yes

170

  1. aMore than one answer is possible